Retinal Vein Occlusion Therapeutics - Pipeline Assessment and Market Forecasts to 2019

News provided by

Aug 06, 2012, 07:22 ET

NEW YORK, Aug. 6, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Retinal Vein Occlusion Therapeutics - Pipeline Assessment and Market Forecasts to 2019

http://www.reportlinker.com/p0869192/Retinal-Vein-Occlusion-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2019.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Retinal Vein Occlusion Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Summary

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Retinal Vein Occlusion Therapeutics market. Its scope includes - - Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Retinal Vein Occlusion Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019. - Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.- Analysis of the current and future competition in the seven key countries Retinal Vein Occlusion Therapeutics market. - Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. - Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Retinal Vein Occlusion Therapeutics market.- Analysis of key recent licensing and partnership agreements in Retinal Vein Occlusion Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to - - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. - Develop business strategies by understanding the trends shaping and driving the global Retinal Vein Occlusion Therapeutics market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Retinal Vein Occlusion Therapeutics market in future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. - What's the next big thing in the global Retinal Vein Occlusion Therapeutics market landscape? – Identify, understand and capitalize.

Table of Contents

1 Table of Contents1 Table of Contents 31.1 List of Tables 51.2 List of Figures 62 Retinal Vein Occlusion Therapeutics - Introduction 72.1 Disease Overview 72.1.1 Types of Retinal Vein Occlusion 72.2 Epidemiology 92.2.1 Prevalence 92.2.2 Incidence 102.2.3 Mortality/Morbidity 112.2.4 Sex 112.2.5 Age 112.2.6 Quality of Life 112.2.7 Pharmacoeconomic Burden 112.3 Etiology and Risk Factors 122.3.1 Systemic Vascular/Atherosclerotic Risk Factors in Retinal Vein Occlusion 122.3.2 Hematological Disorders and other Systemic Conditions 132.3.3 Glaucoma/Ocular Hypertension 132.3.4 Familial Retinal Vein Occlusion 132.4 Pathophysiology 132.5 Signs and Symptoms 142.5.1 Macular Edema 142.5.2 Neovascularization 142.5.3 Neovascular Glaucoma 142.6 Diagnosis 142.7 Treatment and Management Pattern 162.7.1 Medical Approaches for Retinal Vein Occlusion 172.7.2 Laser Treatment 172.7.3 Common Surgical Approaches for Retinal Vein Occlusion 172.7.4 Pharmacological Approaches for Retinal Vein Occlusion 182.7.5 Management of Retinal Vein Occlusion 202.8 Referral Pathway 212.9 GlobalData Pipeline Report Guidance 223 Retinal Vein Occlusion Therapeutics - Market Characterization 233.1 Retinal Vein Occlusion Therapeutics Market Size (2006- 2011) - Global 233.2 Retinal Vein Occlusion Therapeutics Market Forecast (2011- 2019) - Global 243.3 Retinal Vein Occlusion Therapeutics Market Size (2006- 2011) - The US 253.4 Retinal Vein Occlusion Therapeutics Market Forecast (2011- 2019) - The US 263.5 Retinal Vein Occlusion Therapeutics Market Size (2006- 2011) - France 273.6 Retinal Vein Occlusion Therapeutics Market Forecast (2011- 2019) - France 283.7 Retinal Vein Occlusion Therapeutics Market Size (2006- 2011) - Germany 293.8 Retinal Vein Occlusion Therapeutics Market Forecast (2011- 2019) - Germany 303.9 Retinal Vein Occlusion Therapeutics Market Size (2006- 2011) - Italy 313.10 Retinal Vein Occlusion Therapeutics Market Forecast (2011- 2019) - Italy 323.11 Retinal Vein Occlusion Therapeutics Market Size (2006- 2011) - Spain 333.12 Retinal Vein Occlusion Therapeutics Market Forecast (2011- 2019) - Spain 343.13 Retinal Vein Occlusion Therapeutics Market Size (2006- 2011) - The UK 353.14 Retinal Vein Occlusion Therapeutics Market Forecast (2011- 2019) - The UK 363.15 Retinal Vein Occlusion Therapeutics Market Size (2006- 2011) - Japan 373.16 Retinal Vein Occlusion Therapeutics Market Forecast (2010- 2019) - Japan 383.17 Drivers and Barriers for the Retinal Vein Occlusion Therapeutics Market 393.17.1 Drivers for the Retinal Vein Occlusion Therapeutics Market 393.17.2 Barriers for the Retinal Vein Occlusion Therapeutics Market 393.17.3 Opportunity and Unmet Need Analysis 403.18 Key Takeaway 404 Retinal Vein Occlusion Therapeutics - Competitive Assessment 414.1 Overview 414.2 Strategic Competitor Assessment 414.3 Product Profiles for the Major Marketed Products in the Retinal Vein Occlusion Therapeutics Market 424.3.1 Lucentis (ranibizumab) 424.3.2 Ozurdex (dexamethasone intravitreal implant) 434.3.3 Avastin (bevacizumab) 454.4 Key Takeaway 455 Retinal Vein Occlusion Therapeutics - Pipeline Assessment 465.1 Overview 465.2 Strategic Pipeline Assessment 465.3 Retinal Vein Occlusion Therapeutics Pipeline - Pipeline by Phase of Development 475.3.1 Retinal Vein Occlusion Therapeutics - Phase III Pipeline 475.3.2 Retinal Vein Occlusion Therapeutics - Phase II/III Pipeline 475.3.3 Retinal Vein Occlusion Therapeutics - Phase II Pipeline 485.3.4 Retinal Vein Occlusion Therapeutics - Phase I/II 485.4 Retinal Vein Occlusion Therapeutics Market - Pipeline by Mechanism of Action 495.5 Technology Trends Analytic Framework 505.6 Retinal Vein Occlusion Therapeutics - Promising Drugs under Clinical Development 515.7 Molecule Profile for Promising Drugs under Clinical Development 525.7.1 Eylea (aflibercept injection) 525.8 Key Takeaway 536 Retinal Vein Occlusion Therapeutics - Clinical Trials Mapping 546.1 Clinical Trial Mapping Overview 546.2 Clinical Trials by Region/Country (the US, EU5 and Japan) 546.3 Clinical Trials by Phase 556.4 Clinical Trials by Trial Status 566.5 Prominent Sponsors 576.6 Key Companies Participating in Retinal Vein Occlusion Therapeutics Clinical Trials 597 Strategic Assessment 607.1 Key Events Impacting the Future Market 607.2 Retinal Vein Occlusion Therapeutics: Implications for Future Market Competition 618 Retinal Vein Occlusion Therapeutics - Future Players 628.1 Introduction 628.2 Company Profiles 628.2.1 Regeneron Pharmaceuticals, Inc 628.2.2 Novartis AG 648.2.3 Roche (Genentech) 668.2.4 Allergan 689 Retinal Vein Occlusion Therapeutics - Licensing and Partnership Deals 6910 Retinal Vein Occlusion Therapeutics - Appendix 7110.1 Market Definitions 7110.2 Abbreviations 7110.3 Bibliography 7210.4 Research Methodology 7310.4.1 Coverage 7310.4.2 Secondary Research 7310.4.3 Forecasting 7410.4.4 Primary Research 7610.4.5 Expert Panel Validation 7710.5 Contact Us 7710.6 Disclaimer 77

List of Tables

Table 1: Prevalence Rates of Retinal Vein Occlusion by Country/Region 9

Table 2: Prevalent Pool of Retinal Vein Occlusion Patients in the Seven Major Markets 10

Table 3: Recommendations for the Management of Branch Retinal Vein Occlusion 20

Table 4: Recommendations for the Management of Central Retinal Vein Occlusion 21

Table 5: Retinal Vein Occlusion Therapeutics Market, Global, Revenue ($m), 2006- 2011 23

Table 6: Retinal Vein Occlusion Therapeutics Market, Global, Forecast ($m), 2011- 2019 24

Table 7: Retinal Vein Occlusion Therapeutics Market, The US, Revenue ($m), 2006- 2011 25

Table 8: Retinal Vein Occlusion Therapeutics Market, The US, Forecasts ($m), 2011- 2019 26

Table 9: Retinal Vein Occlusion Therapeutics Market, France, Revenue ($m), 2006- 2011 27

Table 10: Retinal Vein Occlusion Therapeutics Market, France, Forecasts ($m), 2011- 2019 28

Table 11: Retinal Vein Occlusion Therapeutics Market, Germany, Revenue ($m), 2006- 2011 29

Table 12: Retinal Vein Occlusion Therapeutics Market, Germany, Forecasts ($m), 2011- 2019 30

Table 13: Retinal Vein Occlusion Therapeutics Market, Italy, Revenue ($m), 2006- 2011 31

Table 14: Retinal Vein Occlusion Therapeutics Market, Italy, Forecasts ($m), 2011- 2019 32

Table 15: Retinal Vein Occlusion Therapeutics Market, Spain, Revenue ($m), 2006- 2011 33

Table 16: Retinal Vein Occlusion Therapeutics Market, Spain, Forecasts ($m), 2011- 2019 34

Table 17: Retinal Vein Occlusion Therapeutics Market, The UK, Revenue ($m), 2006- 2011 35

Table 18: Retinal Vein Occlusion Therapeutics Market, The UK, Forecasts ($m), 2011- 2019 36

Table 19: Retinal Vein Occlusion Therapeutics Market, Japan, Revenue ($m), 2006- 2011 37

Table 20: Retinal Vein Occlusion Therapeutics Market, Japan, Forecasts ($m), 2011- 2019 38

Table 21: Lucentis Phase III Clinical Trial Details 43

Table 22: Number (%) of Patients With ? 15 Letter Improvement from Baseline in Best-Corrected Visual Acuity 44

Table 23: Adverse Reactions Reported by >2% of Patients in the First Six Months 44

Table 24: Retinal Vein Occlusion Therapeutics, Phase III Pipeline, 2012 47

Table 25: Retinal Vein Occlusion Therapeutics, Phase II/III Pipeline, 2012 47

Table 26: Retinal Vein Occlusion Therapeutics, Phase II Pipeline, 2012 48

Table 27: Retinal Vein Occlusion Therapeutics, Phase I/II Pipeline, 2012 48

Table 28: RVO Therapeutics - Most Promising Drugs Under Clinical Development, 2012 51

Table 29: Eylea Phase III Clinical Trial Details 53

Table 30: Retinal Vein Occlusion Therapeutics, Clinical Trials by Country, 2012 54

Table 31: Retinal Vein Occlusion Therapeutics, Clinical Trials by Phase, 2012 55

Table 32: Retinal Vein Occlusion Therapeutics, Clinical Trials by Status, 2012 56

Table 33: Retinal Vein Occlusion Therapeutics, Prominent Sponsors, 2012 58

Table 34: Retinal Vein Occlusion Therapeutics, Global, Key Companies Participating Clinical Trials, 2012 59

Table 35: Regeneron - Ophthalmology Pipeline Products, 2012 63

Table 36: Novartis - Ophthalmology Pipeline Products, 2012 65

Table 37: Roche - Ophthalmology Pipeline Products, 2012 67

Table 38: Allergan, Inc. - Ophthalmology Pipeline Products, 2012 68

Table 39: Retinal Vein Occlusion Therapeutics, Global, Deals, 2009-2011 69

List of Figures

1.2 List of FiguresFigure 1: Branch Retinal Vein Occlusion 7Figure 2: Central Vein Retinal Occlusion 8Figure 3: Ischemic Central Retinal Vein Occlusion 8Figure 4: Nonischemic Central Retinal Vein Occlusion 9Figure 5: KOL Insights, Future Trends in the Prevalence for the RVO in the US and Europe 10Figure 6: Pharmacoeconomic Burden of Retinal Vein Occlusion 12Figure 7: Branch Retinal Vein Occlusion in the Superotemporal Quadrant of the Right Eye 15Figure 8: Nonperfused Central Retinal Vein Occlusion in the Left Eye 15Figure 9: Assessment of Cardiovascular Risk in Patients with Retinal Vein Occlusion 16Figure 10: KOL Insights, Treatment and Management Patterns 16Figure 11: KOL Insights, Usage Patterns for the Pharmacological Treatment Options 19Figure 12: Retinal Vein Occlusion Therapeutics Market, Global, Revenue ($m), 2006- 2011 23Figure 13: Retinal Vein Occlusion Therapeutics Market, Global, Forecast ($m), 2011- 2019 24Figure 14: Retinal Vein Occlusion Therapeutics Market, The US, , Revenue ($m), 2006- 2011 25Figure 15: Retinal Vein Occlusion Therapeutics Market, The US, Forecast ($m), 2011- 2019 26Figure 16: Retinal Vein Occlusion Therapeutics Market, France, Revenue ($m), 2006- 2011 27Figure 17: Retinal Vein Occlusion Therapeutics Market, France, Forecast ($m), 2011- 2019 28Figure 18: Retinal Vein Occlusion Therapeutics Market, Germany, Revenue ($m), 2006- 2011 29Figure 19: Retinal Vein Occlusion Therapeutics Market, Germany, Forecast ($m), 2011- 2019 30Figure 20: Retinal Vein Occlusion Therapeutics Market, Italy, Revenue ($m), 2006- 2011 31Figure 21: Retinal Vein Occlusion Therapeutics Market, Italy, Forecast ($m), 2011- 2019 32Figure 22: Retinal Vein Occlusion Therapeutics Market, Spain, Revenue ($m), 2006- 2011 33Figure 23: Retinal Vein Occlusion Therapeutics Market, Spain, Forecast ($m), 2011- 2019 34Figure 24: Retinal Vein Occlusion Therapeutics Market, The UK, Revenue ($m), 2006- 2011 35Figure 25: Retinal Vein Occlusion Therapeutics Market, The UK, Forecast ($m), 2011- 2019 36Figure 26: Retinal Vein Occlusion Therapeutics Market, Japan, Revenue ($m), 2006- 2011 37Figure 27: Retinal Vein Occlusion Therapeutics Market, Japan, Forecast ($m), 2011- 2019 38Figure 28: Opportunity and Unmet Need in the Retinal Vein Occlusion Therapeutics Market, 2012 40Figure 29: Retinal Vein Occlusion Therapeutics, Strategic Competitor Assessment, 2012 41Figure 30:KOL Insights, Potential Future Pipeline Assets in Retinal Vein Occlusion Therapeutics 46Figure 31: Retinal Vein Occlusion Therapeutics - Pipeline by Phase of Development, 2012 47Figure 32: Retinal Vein Occlusion Therapeutics, Pipeline by Mechanism of Action, 2012 49Figure 33: Retinal Vein Occlusion Therapeutics, Technology Trends Analytics Framework, 2012 50Figure 34: Retinal Vein Occlusion Pipeline, Technology Trends Analytics Framework, Description, 2012 51Figure 35: Retinal Vein Occlusion Therapeutics, Clinical Trials by Country, 2012 54Figure 36: Retinal Vein Occlusion Therapeutics, Clinical Trials by Phase (%), 2012 55Figure 37: Retinal Vein Occlusion Therapeutics, Clinical Trials by Status (%), 2012 56Figure 38: Retinal Vein Occlusion Therapeutics, Overall Sponsors (%), 2012 57Figure 39: Retinal Vein Occlusion Therapeutics, Prominent Sponsors (%), 2012 58Figure 40: Retinal Vein Occlusion Therapeutics, Global, Key Companies Participating Clinical Trials, 2012 59Figure 41: Retinal Vein Occlusion Therapeutics Market, Drivers and Barriers, 2012 60Figure 42: Implications for Future Market Competition in the Retinal Vein Occlusion Therapeutics Market, 2012 61Figure 43: GlobalData Market Size Estimation 74Figure 44: GlobalData Market Forecasting Model 76